Epidermal growth factor receptor biomarkers in non-small-cell lung cancer: a riddle, wrapped in a mystery, inside an enigma.

摘要

In placebo-controlled studies of erlotinib2 and gefitinib,3 subset analyses showed that patients with high EGFR copy had significantly higher ORRs and derived significantly greater survival benefit from treatment. 10~12 Furthermore, in the Iressa Survival Evaluation in Lung Cancer (ISEL) trial, the interaction was qualitative, with low-copy number patients having shorter survival on gefitinib compared with those on with placebo. In contrast, although all studies have shown that patients with EGJ-K-mutated tumors have significantly higher ORRs than those with wild-type EGFR tumors, both groups derive survival benefit from treatment compared with placebo, with the difference in the degree of benefit (quantitative interaction).